LCTX

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for BioTime, Inc. (Note: The request metadata listed "Lineage Cell Therapeutics," but the filing text identifies the registrant as BioTime, Inc.) for the period ended September 30, 1999. BioTime is a development-stage biomedical company focused on synthetic plasma expanders, blood volume substitutes, and organ preservation solutions. On March 31, 1999, the company received FDA approval for its first product, Hextend, and began trading on the American Stock Exchange (AMEX) under the symbol "BTX" in August 1999.

Key Financial Metrics

Operating Expenses: Research and Development (R&D) expenses were $1,957,094 for the quarter and $3,769,100 for the nine-month period. General and Administrative (G&A) expenses were $383,913 for the quarter and $1,496,865 for the nine-month period.

Material Changes vs. Prior Period

• Revenue: Revenue for the three months ended September 30, 1999, was $0, compared to $125,000 in the same period in 1998. However, for the nine months ended September 30, 1999, revenue increased to $1,037,500 from $625,000 in the prior year, driven by the achievement of additional license fee milestones.
• Net Loss: The net loss widened significantly to $2.25 million for the quarter (vs. $1.14 million in 1998) and $4.03 million for the nine months (vs. $2.97 million in 1998).
• R&D Expenses: R&D expenses increased by approximately 110% for the quarter and 55% for the nine-month period compared to 1998. This increase is attributed to expanded laboratory research, a clinical trial in the UK, and a one-time $552,000 expense related to a warrant grant for an endowment.
• Liquidity: Cash and cash equivalents increased from $2.43 million at December 31, 1998, to $6.60 million at September 30, 1999, primarily due to a subscription rights offering in March 1999 that raised approximately $7.33 million.

Guidance, Outlook, and Risks

Outlook and Management Commentary:

• Product Launch: Abbott Laboratories began marketing Hextend in the U.S. during the third quarter of 1999. The company expects to recognize royalty and license fee revenues from these sales in the fourth quarter of 1999.
• Future Operations: Management expects to continue incurring operating losses for the foreseeable future as it funds clinical trials for new products (PentaLyte, HetaCool) and expands global licensing efforts.
• Capital Needs: While current cash is expected to fund operations for the next 12 months, additional financing may be required to complete product development. Future funding may come from equity sales, debt, or licensing fees.

Risks and Contingencies:

• Regulatory Approval: Success depends on obtaining FDA and foreign regulatory approvals for new products and indications.
• Market Acceptance: Sales depend on the outcomes of medical studies comparing Hextend to other products and the willingness of hospitals to add it to formularies.
• Year 2000 Compliance: The company relies on third-party contractors and Abbott for manufacturing and data analysis. While the company's internal systems are compliant, it has no contingency plan if Abbott or suppliers face Y2K disruptions.
• Financing: Inadequate financing could force the company to curtail or suspend operations.

Investor Verification Checklist

• Revenue Recognition Timing: Verify when Abbott reports Hextend sales to BioTime, as revenue recognition is delayed until the receipt of sales reports (expected in Q4 1999).
• License Agreement Terms: Review the specific milestones and royalty rates in the Abbott agreement (Note 4) to understand future revenue potential.
• Cash Burn Rate: Monitor the rate of cash consumption against the $6.6 million cash balance to assess the runway for operations without new financing.
• Clinical Trial Results: Track the results of the UK clinical trial and upcoming U.S. trials for HetaCool and PentaLyte, as these are critical for future product approvals.
• Stock Dilution: Note the outstanding options (530,500 shares) and warrants, which could dilute existing shareholders if exercised.